BIA Separations

BIA Separations is a key technology provider in the downstream processing of large biomolecules for advanced therapeutics. Founded in 1998 and acquired by Sartorius in 2020, the company's core innovation is its patented Convective Interaction Media (CIM) monolithic chromatography columns, which offer high-flow, low-pressure separation ideal for fragile entities like AAVs and mRNA. The company has expanded its offering to include integrated analytical platforms (PATfix) and biomanufacturing development services, positioning itself as a critical enabler for the rapidly growing cell and gene therapy sector. Its business model is based on selling consumables, equipment, and services to biopharmaceutical developers and manufacturers.

Proprietary Convective Interaction Media (CIM) monolithic chromatography columns and integrated PATfix analytical platforms for the purification and analysis of large biomolecules (viral vectors, nucleic acids, LNPs).

BIA Separations is a recognized leader in monolithic chromatography, competing with other chromatography media giants like Cytiva (Capto resins), Bio-Rad, and Tosoh Bioscience, which offer resins for large biomolecules. It also faces competition from specialized purification tool companies and analytical instrument providers. Its acquisition by Sartorius strengthens its position by combining its niche technology with a broad bioprocess ecosystem.